Gumintad, Lea Mae P.

HRN: 24-99-46  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/19/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/19/2024
05/26/2024
IV
600mg
Q6
Hirschsprung Disease; Post-op
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Intra-abdominal    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: